Ketoprofen/nifedipine

Drug Profile

Ketoprofen/nifedipine

Alternative Names: OMS-201

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator Omeros Corporation
  • Class Antispasmodics; Dihydropyridines; Muscle relaxants; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Calcium channel antagonists; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Inflammation; Pain; Spasm

Most Recent Events

  • 16 Mar 2017 Omeros Corporation has patent protection for for ketoprofen/nifedipine for pain, inflammation and spasm in USA and ex-US countries
  • 04 May 2012 Omeros plans a phase II programme for Inflammation, Pain and Spasm
  • 30 Dec 2010 Final adverse events data from a Phase-I/II trial in Inflammation, Pain and Spasm released by Omeros
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top